0001493152-21-009302.txt : 20210420 0001493152-21-009302.hdr.sgml : 20210420 20210420214421 ACCESSION NUMBER: 0001493152-21-009302 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210416 FILED AS OF DATE: 20210420 DATE AS OF CHANGE: 20210420 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rivard Paul CENTRAL INDEX KEY: 0001857479 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36268 FILM NUMBER: 21839326 MAIL ADDRESS: STREET 1: C/O AKERS BIOSCIENCES, INC. STREET 2: 1185 AVENUE OF THE AMERICAS, 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MyMD Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001321834 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1185 AVENUE OF THE AMERICAS STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 856-848-8698 MAIL ADDRESS: STREET 1: 1185 AVENUE OF THE AMERICAS STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Akers Biosciences, Inc. DATE OF NAME CHANGE: 20170413 FORMER COMPANY: FORMER CONFORMED NAME: Akers Biosciences Inc DATE OF NAME CHANGE: 20050325 4 1 ownership.xml X0306 4 2021-04-16 0 0001321834 MyMD Pharmaceuticals, Inc. MYMD 0001857479 Rivard Paul 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK, NY 10036 0 1 0 0 EVP of Operations, GC Stock Option (Right to Buy) 2.5913 2021-04-16 4 A 0 77180 A 2023-04-16 Common Stock 77180 77180 D Stock Option (Right to Buy) 2.5913 2021-04-16 4 A 0 77180 A 2023-04-16 Common Stock 77180 77180 I See footnote Received in exchange for a stock option to acquire 200,000 shares of common stock of a private company formerly known as "MyMD Pharmaceuticals, Inc." (the "Former Entity") at $1.00 per share in connection with the merger of the Former Entity with and into a wholly owned subsidiary of the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's common stock was $4.94 per share. These options are fully vested and exercisable. Received in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share in connection with the Merger. These shares are jointly held by the reporting person and Jennifer Rivard as trustees for the Paul Rivard and Jennifer Rivard Revocable Living Trust. /s/ Paul Rivard 2021-04-20